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ABSTRACT
Companies and healthcare providers are developing and implementing new
applications of medical articial intelligence, including the articial intelli-
gence sub-type of medical machine learning (MML).MML is based on the
application of machine learning (ML) algorithms to automatically identify
patterns and act on medical data to guide clinical decisions. MML poses
challenges and raises important questions, including (1) How will regula-
tors evaluate MML-based medical devices to ensure their safety and e ec-
tiveness? and (2) What additional MML considerations should be taken
into account in the international context? To address these questions, we
analyze the current regulatory approaches toMML in the USA and Europe.
We then examine international perspectives and broader implications,
discussing considerations such as data privacy, exportation, explanation,
training set bias, contextual bias, and trade secrecy.
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INTRODUCTION
The term ‘articial intelligence’ (AI) has been broadly dened as ‘the science and
engineering ofmaking intelligentmachines, especially intelligent computer programs’.1
Within the eld of AI, machine learning (ML) can be used to design and train algo-
rithms to learn, identify patterns, and act on data. Depending on their design, ML
algorithms can be ‘locked’ or allowed to continuously learn from data to adapt and
optimize their performance in real-time.2
AI/ML has found applications in basic biomedical research, translational research,
and clinical practice.3Companies andhealthcareproviders are currently investingheav-
ily in developingmedical gradeAI/MLapplications (hereinaermedical articial intel-
ligence—‘MAI’ and medical machine learning—‘MML’). Examples of applications
include AI-driven X-ray image analysis,4 smartphone apps that detect skin cancer,5
and the use of AI-driven monitoring systems to identify elderly patients at risk of
falling.6 AI is also being applied in biomarker and drug discovery7 and recently, the
US Food and Drug Administration (FDA) approved the rst digital pill, consisting of
a drug combined with an ingestible electronic sensor that helps to improve patients’
medication adherence.8
These kinds of technologies may increase patient safety and help to control, for
example, the use of antibiotics to reduce antimicrobial resistance. Yet, they also raise
concerns and challenges with regard to safety, e ectiveness, transparency, data sharing,
property rights, antitrust, cybersecurity, privacy, and algorithmic bias and discrim-
ination. Hence, regulators, such as the US FDA, the European Medicines Agency
(EMA), and national competent authorities for medical devices are working to gure
out how to interpret, apply, ormodify their existing regulatory frameworks in theMML
1 FDA, Articial Intelligence and Machine Learning in Software as a Medical Device, https://www.fda.gov/
medical-devices/soware-medical-device-samd/articial-intelligence-and-machine-learning-soware-
medical-device (accessed June 13, 2019). Referring to JohnMcCarthy,What Is Articial Intelligence?, http://
jmc.stanford.edu/articles/whatisai/whatisai.pdf (accessed Jun. 13, 2019).
2 FDA, Proposed Regulatory Framework for Modications to Articial Intelligence/Machine Learning (AI/ML)—
Based Software as a Medical Device (SaMD), https://www.fda.gov/media/122535/download (accessed Jun.
13, 2019), at 3.
3 Kun-Hsing Yu, Andrew L. Beam, Isaac S. Kohane, Articial intelligence in healthcare, 2 Nat Biomed Eng 719
(2018).
4 Ahmed Hosny, Chintan Parmar, John Quackenbush, Lawrence H. Schwartz, Hugo J. W. L. Aerts, Articial
intelligence in radiology, 18 Nat RevCancer 500 (2018).
5 GeorgeA.Zakhem,CatherineC.Motosko,Roger S.Ho,HowShouldArticial Intelligence Screen for SkinCancer
and Deliver Diagnostic Predictions to Patients?, 154 JAMADermatol 1383 (2018).
6 E. Ramanujam, S. Padmavathi, A Vision-Based Posture Monitoring System for the Elderly Using Intelligent Fall
Detection Technique, in Guide toAmbient Intelligence in the IoTEnvironment (ZaighamMahmood
ed., 2019).
7 Alex Zhavoronkov, Articial Intelligence for Drug Discovery, Biomarker Development, and Generation of Novel
Chemistry, 15 Mol Pharm 4311 (2018).
8 Proteus Digital Health, Otsuka and Proteus® Announce the First U.S. FDA Approval of a Digital Medicine Sys-
tem:AbilifyMyCite® (aripiprazole tabletswith sensor), https://www.proteus.com/press-releases/otsuka-and-
proteus-announce-the-rst-us-fda-approval-of-a-digital-medicine-system-abilify-mycite (accessed Jun. 13,
2019). See also FDA, NDA Approval 207202, https://www.accessdata.fda.gov/drugsatfda_docs/appletter/
2017/207202Orig1s000ltr.pdf (accessed Jun. 13, 2019). FDA, Label of Abilify MyCite (aripiprazole tablets
with sensor), https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207202lbl.pdf (accessed Jun.
13, 2019). For more information, see Sara Gerke, Timo Minssen, Helen Yu, I. Glenn Cohen, A Smart Pill
to Swallow: Legal and Ethical Issues of Ingestible Electronic Sensors, Nat Electron (2019, forthcoming).
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context. Several changes to the current frameworks are being proposed and discussed
around the globe, including regulatory frameworks for AI/ML-based medical device
soware, privacy, and cybersecurity. In addition, ethical frameworks have increasingly
been demanded and developed by di erent stakeholders.9
In the following, we focus on two foundational questions in this narrative: (1)
How will regulators evaluate MML-based medical devices to ensure their safety and
e ectiveness? and (2) What additional MML considerations should be taken into
account in the international context?
USREGULATORYAPPROACH
According to a recent forecast, AI has the potential to create $150 billion in yearly
savings for the US healthcare economy in the next 7 years; the AI health market is
expected to grow to $6.6 billion by 2021.10 MML regulation and the path to market
are key concerns for AI developers. The FDA has recognized the importance of digital
health products generally and AI specically, releasing a Digital Health Innovation
Action Plan in July 2017 that proposed new guidances (some since issued), increased
in-house expertise through hiring, and a more exible approach to approving soware
products (implemented through the pilot Pre-Cert program).11 Many of the recent
developments discussed in this section arise from the Action Plan.
The rst step for manufacturers or developers intending to market an MML prod-
uct is to determine whether the product is intended as a ‘general wellness product’
(consumer-grade) or as a ‘medical device’ (clinical-grade). The recently enacted 21st
Century Cures Act contains an important exclusion for soware intended ‘for main-
taining or encouraging a healthy lifestyle’ that is ‘unrelated to the diagnosis, cure,
mitigation, prevention, or treatment of a disease or condition’.12 Such soware does
not fall under the medical device denition and FDA does not intend to examine
low risk wellness products according to its Guidance ‘General Wellness: Policy for Low
Risk Devices’.13 Examples include apps that use ML but (1) the intended uses involve
claims about sustaining or o ering general improvement to functions associated with a
general state of health that ‘do not make any reference to diseases or conditions (eg
claims to promote weight management, sleep management, physical tness) or (2)
claims that make a reference to diseases or conditions (eg intended uses to promote,
track, and/or encourage choices which as part of a healthy lifestyle that “may help to
reduce the risk” or “may help living well”’ with certain chronic diseases or conditions,
where the claim is generally accepted because the associations are described in peer-
reviewed scientic publications or ocial statements made by healthcare professional
organizations). However, if the ML product is labeled, promoted, or used in a manner
that meets the denition of ‘device’ in section 201(h) of the Federal Food Drug &
9 Luciano Floridi, Establishing the rules for building trustworthy AI, 1 Nat Mach Intell 261 (2019).
10 Accenture, Articial Intelligence (AI): Healthcare’s New Nervous System, https://www.accenture.com/us-en/
insight-articial-intelligence-healthcare (accessed Jun. 13, 2019).
11 FDA, Digital Health Innovation Action Plan, https://www.fda.gov/media/106331/download (accessed Jan.
29, 2020).
12 21st Century Cures Act, sec. 3060. See also Federal Food Drug & Cosmetic Act, sec. 520(o)(1)(B).
13 FDA, General Wellness: Policy for Low Risk Devices. Guidance for Industry and Food and Drug Administration
Sta  , https://www.fda.gov/media/90652/download (accessed Jun. 15, 2019).
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Cosmetic (FD&C) Act, it will be regulated by the FDA as a ‘medical device’ and
require pre-marketing and post-marketing regulatory controls, including: (1) FDA
establishment registration, device listing, andpre-market notication requirements (21
CFR Part 807); (2) labeling requirements (21 CFR Part 801 and 21CFR 809.10); (3)
current good manufacturing practice (CGMP) and quality system (QS) requirements
(21CFRPart 820); and (4)medical device reporting requirements (21CFRPart 803).
Accordingly, the manufacturer/developer should carefully formulate the intended
use, claims, labeling, and associated marketing of the MAI/MML product, since these
decisions have signicant regulatory consequences. A medical device is dened in
201(h) of the FD&C Act to include ‘an instrument, apparatus, implement, machine
[ . . . ] which is intended for use in the diagnosis of disease or other conditions, or
in the cure, mitigation, treatment, or prevention of disease’ that does not achieve its
‘primary intended purposes through chemical actionwithin or on the body ofman’ and
which is ‘not dependent upon being metabolized for the achievement of’ its primary
intended purposes. For example, Apple’s electrocardiogram (ECG) app, intended for
use with the Apple’s watch to ‘create, record, store, transfer, and display a single channel
electrocardiogram (ECG) similar to a Lead I ECG’,14 and Apple’s irregular rhythm
notication feature, intended to identify and notify the user of episodes of irregular
heart rhythms,15 are bothmedical devices and subject to FDA regulatory controls even
though the apps are ‘not intended to interpret or take clinical action’ and the resulting
medical device ‘is not intended to provide a diagnosis’.16
The FDA classies medical devices in three classes based on their risk prole,
intended use, indications for use, technological characteristics, and the regulatory
controls necessary to provide a reasonable assurance of safety and e ectiveness.17 The
class of the device determines the type of pre-marketing submission or application
required for marketing. The FDA reviews medical devices through one of three pre-
market pathways: (1) the 510(k) pre-market notication/clearance, (2) De Novo
classication, and (3) pre-market approval (PMA) pathways. Low-risk devices (Class
I) are subject to general controls, but most are exempted from 510(k) pre-market
notication. Moderate-risk devices (Class II) are subject to general controls, special
controls, and typically require a 510(k) pre-market notication (unless the specic
product code is 510(k) Exempt) or De Novo classication process. High-risk devices
(Class III) require general controls and a PMA application.18 As an illustrative exam-
ple, the FDA recently reviewed the Apple’s apps mentioned above through the De
Novo classication process and classied them as Class II medical devices.19 General
14 FDA, Apple Inc. DEN180044, https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180044.pdf
(accessed Jun. 13, 2019).
15 FDA, Apple Inc. DEN180042, https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180042.pdf
(accessed Jun. 13, 2019).
16 FDA, Apple Inc. DEN180044, https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180044.pdf
(accessed Jun. 13, 2019).
17 FDA, Step 3: Pathway to Approval, https://www.fda.gov/patients/device-development-process/step-3-
pathway-approval (accessed Jun. 15, 2019).
18 For more information on the classication process and premarket process, see FDA, How to Study
and Market Your Device, https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-
assistance/how-study-and-market-your-device (accessed Jun. 15, 2019).
19 FDA, Apple Inc. DEN180044, https://www.accessdata.fda.gov/cdrh_docs/pdf18/DEN180044.pdf
(accessed Jun. 13, 2019). FDA, Apple Inc. DEN180042, https://www.accessdata.fda.gov/cdrh_docs/pdf18/
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controls apply to all medical devices (unless exempted by regulations) and include
FDA establishment registration and device listing, pre-market notication (eg FDA
510 k submission or De Novo classication), and records and reports on devices
(eg quality management system, device tracking, unique device identication system,
adverse event reporting, and reports of removals and corrections). Special controls
are regulatory requirements for class II devices (ie devices for which general controls
alone are insucient to provide reasonable assurance of the safety and e ectiveness
of the device). These include (1) performance standards, (2) pre-market clinical data
requirements, (3) post-market surveillance, (4) special labeling requirements, (5)
patient registries, and (6) guidelines.
Depending on the specic application, MML algorithms can be an integral part of
the hardware of amedical device and necessary to achieve its intended use (Soware in
a Medical Device) or standalone soware intended to be used for medical purposes
without being part of a hardware medical device (soware as a medical device or
‘SaMD’).20 Soware apps designed to be used on consumer-grade devices such as an
Apple’s watch are examples of SaMDs since the underlying hardware is not itself a
medical device. Recognizing the regulatory challenges of soware as standalone med-
ical devices, the International Medical Device Regulators Forum (IMDRF)‘s SaMD
working group has authored a framework, principles, and guidance for SaMD. The
IMDRF framework for risk categorizationof SaMDhas four categories basedon(1) the
signicance of the information provided by the SaMD to a healthcare decision (inform
clinical management, drive clinical management, treat, or diagnose) and (2) the state
of healthcare situation or condition (non-serious, serious, and critical).21 For example,
as shown inTable 1, a SaMD thatmerely informs clinical management of a non-serious
condition will be categorized as Level I (lowest risk), while a SaMD intended to treat
or diagnose a critical condition as a Level IV (highest risk).
The MAI/MML devices the FDA has reviewed to date have ‘locked’ algorithms
that do not automatically change over time as new data are collected. In April 2019,
the FDA published a discussion paper that proposes a new regulatory approach that
would allow AI/ML-SaMD to continually improve (ie to learn, adapt, and optimize
performance in real-time) while providing e ective safeguards.22 Consistent with the
IMDRF denition, in the proposed FDA, AI/ML-SaMD regulatory approach ‘SaMD’
is dened as ‘soware intended to be used for one or more medical purposes that
perform these purposes without being part of a hardware medical device’.23 Medical
purposes are ‘purposes that are intended to treat, diagnose, cure, mitigate, or prevent
DEN180042.pdf (accessed Jun. 13, 2019). FDA, Apple Inc. DEN180042, https://www.accessdata.fda.gov/
cdrh_docs/pdf18/DEN180042.pdf (accessed Jun. 13, 2019).
20 FDA, Software as a Medical Device, https://www.fda.gov/medical-devices/digital-health/soware-medical-
device-samd (accessed Jun.e 13, 2019).
21 IMDRF, “Software as a Medical Device”: Possible Framework for Risk Categorization and Corresponding
Considerations, http://www.imdrf.org/docs/imdrf/nal/technical/imdrf-tech-140918-samd-framework-
risk-categorization-141013.pdf (accessed Jun. 15, 2019), at 10–4.
22 FDA, Proposed Regulatory Framework for Modications to Articial Intelligence/Machine Learning (AI/ML)—
Based Software as a Medical Device (SaMD), https://www.fda.gov/media/122535/download (accessed Jun.
13, 2019), at 3.
23 Id. at 2.
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Table 1. SaMD risk characterization matrix developed by the IMDRF–SaMD
Working Group (framework for risk categorization). It is expected that MML
SaMDs will be allowed to continually change by ‘adaptive learning’ for Level I
categories (eg informing clinical management of non-serious conditions). This
is considered a change in performance due to learning from data and would not
require a further review by FDA.However, a change in the SaMD intended use (eg
from ‘informing clinical management’ of a non-serious condition to ‘diagnosing’
of a serious or critical condition) would likely require a submission to the FDA for
appropriate review (eg 510 k, De Novo, PMA).
State of healthcare
situation or condition








Critical IV III II
Serious III II I
Non-serious II I I
disease or other conditions’.24 The proposed framework analyzes the types of modi-
cations (eg changes to performance, inputs, or intended uses) in the context of a total
product lifecycle regulatory approach to MAI/MML-SaMD based on QS and good
MLpractices. This framework does not apply to ‘non-device’ soware functions.25 The
FDAplans to issuedraguidancebasedon the input received fromthediscussionpaper
but admits that additional statutory authority may be needed to fully implement the
proposed framework.26
EUROPEANUNIONREGULATORYAPPROACH
Similar to the FDA, the EMA has also acknowledged the signicance of digital health
products and their interface with Big Data, MML, and MAI. Although many activities
were put on halt due to the withdrawal of the United Kingdom from the European
Union (EU) and the resultingmove of the EMAheadquarters, the EMAand theHeads
of Medicines Agencies (HMA) have been working intensively on understanding the
acceptability of big data-derived evidence in support of the evaluation and supervision
of medicines. Their rst Joint Big Data Taskforce report, published in February 2019,
set out a number of steps towards regulatory acceptance of big data, ranging from
data standardization and the need to link genomics data with clinical outcomes to
the pressing demand for timely access to data that is representative of the European
24 Id. at. 2.
25 Id. at 4.
26 Id. at 4. For more information on the FDA’s discussion paper and the treatment of “locked” versus “adaptive”
algorithms, see Boris Babic, Sara Gerke, Theodoros Evgeniou, I. Glenn Cohen, Algorithms on regulatory
lockdown in medicine, 366 SCIENCE 1202 (2019).
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population.27Most recently, in January 2020, theHMA–EMAJointBigDataTaskforce
published their second report, which proposes 10 priority actions for the European
medicines regulatory network to evolve its approach to data use and evidence gener-
ation to best use big data to facilitate innovation and public health.28 Moreover, on 19
February2020, theEuropeanCommissionpublished aWhitePaper topromote aEuro-
pean ecosystem of excellence and trust in AI (1), a data strategy communication (2)
and a report on the safety and liability aspects of AI.29However, the focus has been laid
so far on the development of enabling infrastructures, rather than specic guidelines on
the use of MML andMAI in drug development, medical procedures, and devices.
As a general requirement, allmedical devices and in vitrodiagnosticmedical devices,
including MML devices, must comply with the CE marking requirements under the
relevant EU regulatory frameworks to be lawfully marketed within Europe.30 On
25 May 2017, two major regulatory changes entered simultaneously into force, which
are highly relevant for medical device manufacturers: EU Regulation 2017/745 on
medical devices (MDR)31 andEURegulation 2017/746on in vitrodiagnosticmedical
devices (IVDR).32 The MDR will repeal the Directive 93/42/EEC concerning med-
ical devices (MDD)33 and the Directive 90/385/EEC on active implantable medical
27 HMA, EMA, HMA-EMA Joint Big Data Taskforce, https://www.ema.europa.eu/en/documents/minutes/
hma/ema-joint-task-force-big-data-summary-report_en.pdf (accessed Feb. 13, 2020).
28 HMA, EMA,HMA-EMA Joint Big Data Taskforce Phase II report: ‘Evolving Data-Driven Regulation’, https://
www.ema.europa.eu/en/documents/other/hma-ema-joint-big-data-taskforce-phase-ii-report-evolving-
data-driven-regulation_en.pdf (accessed Feb. 13, 2020). See also the Priority Recommendations in the 2nd
report, https://www.ema.europa.eu/en/documents/other/priority-recommendations-hma-ema-joint-big-
data-task-force_en.pdf (accessed Feb. 13, 2020). The 10 priority recommendations from the report include:
(1) Deliver a sustainable platform to access and analyze healthcare data from across the EU, (2) Establish
an EU framework for data quality and representativeness, (3) Enable data discoverability, (4) Develop EU
Network skills in Big Data, (5) Strengthen EU Network processes for Big Data submissions, (6) Build EU
Network capability to analyze Big Data, (7) Modernize the delivery of expert advice, (8) Ensure data are
managed and analyzed within a secure and ethical governance, (9) Collaborate with international initiatives
on Big Data, (10) Create an EU Big Data ‘stakeholder implementation forum.
29 Cf. EU White Paper On Articial Intelligence–A European approach to excellence and trust, Brus-
sels, 19.2.2020 COM(2020) 65 nal, https://ec.europa.eu/info/sites/info/les/commission-white-paper-
articial-intelligence-feb2020_en.pdf (accessed Feb. 25, 2020), Communication from the Commission, A
European strategy for data Brussels, 19.2.2020 COM(2020) 66 nal, https://ec.europa.eu/info/sites/info/
les/communication-european-strategy-data-19feb2020_en.pdf (accessed Feb. 25, 2020), Report from the
Commission on the safety and liability implications of Articial Intelligence, the Internet of Things and
robotics, Brussels, 19.2.2020COM(2020)64nal, https://ec.europa.eu/info/sites/info/les/report-safety-
liability-articial-intelligence-feb2020_en_1.pdf (accessed Feb. 25, 2020).
30 See eg Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on
medical devices, amending Directive 2001/83/EC, Regulation (EC)No 178/2002 and Regulation (EC)No
1223/2009 and repealing Council Directives 90/385/EEC and 93/42/EEC [2017]OJ L117/1 (MDR), Art.
20. See also egRegulation (EU)2017/746of theEuropeanParliament andof theCouncil of 5April 2017on in
vitro diagnosticmedical devices and repealingDirective 98/79/EC andCommissionDecision 2010/227/EU
[2017] OJ L117/176 (IVDR), Art. 18.
31 Regulation (EU)2017/745of theEuropeanParliament andof theCouncil of 5April 2017onmedical devices,
amending Directive 2001/83/EC, Regulation (EC) No 178/2002 and Regulation (EC) No 1223/2009 and
repealing Council Directives 90/385/EEC and 93/42/EEC [2017] OJ L117/1.
32 Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro
diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU
[2017] OJ L117/176.
33 Council Directive 93/42/EEC of 14 June 1993 concerning medical devices [1993] OJ L169/1. For the
di erences between a directive and a regulation, see Treaty on the Functioning of the European Union, Art.
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devices (AIMD),34 whereas the IVDRwill replace the Directive 98/79/EC on in vitro
diagnosticmedical devices (IVDD)35 andCommissionDecision 2010/227/EU.36 ,37
Since neither the MDR nor the IVDR includes a ‘grandfathering’ provision, all
currently marketed medical devices and in vitro diagnostic medical devices must be
recertied in conformity with the new requirements.38 The new requirements must
generally be fullled by 26May 2020 for the MDR and 26May 2022 for the IVDR.39
Formedical AI developers, the newMDR is particularly relevant. TheMDRcontin-
ues to divide devices into classes, taking into account risks associated with their man-
ufacture and technical design.40 There are four classes of medical devices of increasing
risk: Class I, Class IIa, Class IIb, and Class III.41
The MDR changes the EU regulatory landscape for MML devices by introducing,
inter alia, heightened requirements for post-market surveillance42 and medical device
traceability.43 Most signicantly, ‘medical device’ is dened more broadly and now
includes soware for the ‘prediction’ and ‘prognosis’ of disease.44 Under the MDR,
some currently marketed devices will shi to higher classes. In particular, the MDR
introduces a new classication rule for soware. For example, Section 6.3 of Chapter
III of Annex VIII (Rule 11) of the MDR provides that ‘Soware intended to provide
information which is used to take decisions with diagnosis or therapeutic purposes
is classied as class IIa, except if such decisions have an impact that may cause: —
death or an irreversible deterioration of a person’s state of health, in which case it
is in class III; or, —a serious deterioration of a person’s state of health or a surgical
intervention, in which case it is classied as class IIb. Soware intended to monitor
physiological processes is classied as class IIa, except if it is intended for monitoring
of vital physiological parameters, where the nature of variations of those parameters is
such that it could result in immediate danger to the patient, in which case it is classied
as class IIb. All other soware is classied as class I’. Notably, SaMD intended tomerely
288. In particular, a regulation is directly applicable in all EUMember States, whereas a directive needs to be
transposed into national law.
34 Council Directive 90/385/EEC of 20 June 1990 on the approximation of the laws of the Member States
relating to active implantable medical devices [1990] OJ L189/17.
35 Directive 98/79/ECof the European Parliament and of theCouncil of 27October 1998 on in vitro diagnostic
medical devices [1998] OJ L331/1.
36 Commission Decision of 19 April 2010 on the European Databank on Medical Devices (Eudamed)
(2010/227/EU) [2010] OJ L102/45.
37 MDR, Art. 122; IVDR, Art. 112.
38 TÜV Süd, Medical Device Regulation, https://www.tuvsud.com/en/industries/healthcare-and-medical-
devices/medical-devices-and-ivd/medical-device-market-approval-and-certication/medical-device-




39 MDR, Art. 120, 123; IVDR, Art. 110, 113.
40 MDR, Recital 58.
41 MDR, Recital 58, Art. 51 and Annex VIII.
42 MDR, Arts. 82–6 and Annex III.
43 See eg the Unique Device Identication system (“UDI system”) in MDR, Art. 27 and Part C of Annex VI,
which “shall allow the identication and facilitate the traceability of devices, other than custom-made and
investigational devices.” See also IVDR, Art. 24.













Medical device denition ‘An instrument, apparatus, implement,
machine [ . . . ] which is intended for use in
the diagnosis of disease or other conditions,
or in the cure, mitigation, treatment, or
prevention of disease’ that does not achieve
its ‘primary intended purposes through
chemical action within or on the body of
man’ and which is ‘not dependent upon
being metabolized for the achievement of’
its primary intended purposes (201(h) of
the FD&CAct)
‘Any instrument, apparatus, appliance, soware, implant, reagent,
material, or other article’ intended by the manufacturer to be
used, alone or in combination, for human beings for one or more
of the following specic medical purposes:
• Diagnosis, prevention, monitoring, prediction, prognosis,
treatment, or alleviation of disease
• Diagnosis, monitoring, treatment, alleviation of, or
compensation for, an injury or disability
• Investigation, replacement, or modication of the anatomy
or of a physiological or pathological process or state
• Providing information by means of in vitro examination of
specimens derived from the human body, including organ,
blood, and tissue donations,
and which does not achieve its principal intended action by
pharmacological, immunological, or metabolic means, in or on
the human body, but which may be assisted in its function by















Classication of medical devices Three classes based on their risk prole,
intended use, indications for use,
technological characteristics, and the
regulatory controls necessary to provide a
reasonable assurance of safety and
e ectiveness:
Four classes of medical devices, taking into account risks
associated with their manufacture and technical design:




• Soware in a medical device ‘Soware’, which drives a device or inuences the use of a device,
shall fall within the same class as the device
➔ Soware used to ‘drive or control’ the
medical device hardware
If the soware is independent of any other device, it shall be
classied in its own right” (MDR, Section 3.3. of Chapter II of
Annex VIII)
➔ Soware required by a hardware
medical device to perform the hardware’s
medical device intended use, even if sold
separately from the hardware medical
device
‘Soware’ intended to provide information which is used to take
decisions with diagnosis or therapeutic purposes is classied as
















• Soware as a medical device —death or an irreversible deterioration of a person’s state of
health, in which case it is in Class III; or,
➔ soware intended to be used for one or more
medical purposes that perform these purposes
without being part of a hardware medical device
—a serious deterioration of a person’s state of health or a surgical
intervention, in which case it is classied as Class IIb
•Not all soware is classied as a ‘medical device’
under the FD&CAct. Non-device soware
functions include:
Soware intended to monitor physiological processes is classied
as Class IIa, except if it is intended for monitoring of vital
physiological parameters, where the nature of variations of
those parameters is such that it could result in immediate
danger to the patient, in which case it is classied as Class IIb
a) Soware functions that are intended ‘for
administrative support of a healthcare facility’
All other soware is classied as Class I” (MDR, Section 6.3 of
Chapter III of Annex VIII (Rule 11))
b) Soware function that are intended ‘for
maintaining or encouraging a healthy lifestyle’
• Rule 11MDR does not explicitly mention or refer to the new
terminology ‘prediction’ and ‘prognosis’ of disease in Art. 2
c) Soware functions that are intended ‘to serve as
electronic patient records’
•However, the concept of ‘prediction’ and ‘prognosis’ of a
disease might be embedded into the formulation: ‘Soware
intended to provide information [ . . . ] used to take decisions
with diagnosis or therapeutic purposes’
d) Soware function that are intended ‘for
transferring, storing, converting formats, or
displaying clinical laboratory test or other device
data and results’, and
•MostMML-based medical devices will be classied as Class IIa
(even if the monitoring is not intended for diagnosis or
therapeutic purposes) or Class IIb if the MML SaMD
monitors vital physiological parameters (eg heart rate, blood
pressure respiration)
e) Certain clinical decision support soware

















•CGMP and QS requirements (21 CFR Part 820) Post-market surveillance:
•Medical device reporting requirements (21 CFR
Part 803)
‘All activities carried out by manufacturers in cooperation with
other economic operators to institute and keep up to date a
systematic procedure to proactively collect and review
experience gained from devices they place on the market, make
available on the market or put into service for the purpose of
identifying any need to immediately apply any necessary
corrective or preventive actions’ (Art. 2 (60)MDR)
• Recalls, corrections, and removal (21 CFR 7, 21
CFR 806, 21 CFR 810)
• Post-market surveillance system (MDR, Art. 83)
•Medical device tracking ➔ For all devices
➔ For certain Class II and Class III devices (21
CFR Part 821)
• Post-market surveillance plan (MDR, Art. 84)
• Post-market surveillance studies • Post-market surveillance report (MDR, Art. 85)
➔Certain Class II and Class III devices (FD&C
Act, Sec. 522)
➔ For Class I devices
• Post-approval studies • Periodic safety update reports (PSUR) (MDR, Art. 86MDR)




















FDA • EMA is not the primary regulator for medical devices
•Medical devices are regulated by theMember States and by
national competent authorities appointed by theMember
States
•Member States can designate independent accredited ‘notied
bodies’ to conduct the required conformity assessments





FDA’s discussion paper on AI/ML-based SaMD48 Lack of specic guidelines on the use of MAI/MML devices.
The focus is laid on the development of enabling
infrastructures. This might change in the future when the
MDR becomes e ective on 26May 2020
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‘monitor physiological processes’ will be classied Class IIa or higher. Accordingly, it
is expected that most MML-based medical devices will be classied as Class IIa (even
if the monitoring information is not intended for diagnosis or therapeutic purposes)
or Class IIb if the MML SaMDmonitors vital physiological parameters (eg heart rate,
blood pressure, and respiration). This implies that mostMML SaMDwill be subjected
to a conformity assessment, including the approval of the technical documentation by
a notied body. The new Rule 11 surprisingly does not mention or refer to the new
terminology ‘prediction’ and ‘prognosis’. This raises the question if this omission is a
mere oversight, or if the concept of prediction and prognosis of a disease is embedded
into the following formulation: ‘Soware intended to provide information [ . . . ] used
to take decisions with diagnosis or therapeutic purposes’.45
In contrast to FDA in the USA, EMA is not the primary regulator for medical
devices. Instead, medical devices are regulated by the Member States who can des-
ignate independent accredited ‘notied bodies’ to conduct the required conformity
assessments and by national competent authorities appointed by the Member States
that are, inter alia, responsible for monitoring notied bodies.46 In the case of low-
risk devices (ie Class I), the manufacturers are able to ‘self-certify’ the conformity
assessment without or with limited involvement of a notied body (Table 2).47
OTHERREGULATORY PERSPECTIVES ANDBROADER IMPLICATIONS
While there are country-specic di erences with regards to the particular pre-market
and post-market review procedures, most developed jurisdictions regulate medical
devices similarly to the US or European models.
In China, the National Medical Products Administration (NMPA), formerly the
China Food and Drug Administration, is responsible for pharmaceuticals and medical
device regulation.49 NMPA also classies medical devices in three categories and
conducts pre-market approval and PMA. The increased medical device regulatory
convergence across these jurisdictions is due, in part, to thework of the IMDRFand the
adoption of ISO standards for medical devices (eg ISO 13485:2016-Medical Devices-
QualityManagement Systems-Requirements forRegulatoryPurposes).The IMDRF is
a voluntary groupofmedical device regulatorswho is continuing theworkof theGlobal
Harmonization Task Force (GHTF) on medical devices with the overall objective of
accelerating internationalmedical device regulatoryharmonizationandconvergence.50
It includes representatives from the medical device regulatory authorities of Australia,
45 See also Stephan Buttron, Ce Marking of Digital Health Technologies: Stricter Rules for Medical Device Soft-
ware under the EU MDR, https://www.namsa.com/european-market/mdr-stricter-rules-medical-device-
soware/ (accessedFeb. 13, 2020), adding: “However, the underlying principle in the rst paragraphofAnnex
VIII Rule 11 suggests that information that is used to make a diagnostic and/or therapeutic decision for a
patient falls under this rule.This provision is understoodas information that provides timely (ie immediate)—
and in certain cases—near-future decision-making processes for a specic patient by a qualied health care
professional. It does not suggest collecting patient data for the intended purpose of a prognosis and/or
prediction of a future state of health for a patient.”.
46 MDR, Art. 35.
47 MDR, Recital 60 and Art. 52(7).
47 MDR, Recital 60 and Art. 52(7).
49 IMDRF,Home page, http://www.imdrf.org/ (accessed Jun. 17, 2019).
50 Id.
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Brazil, Canada, China, EU, Japan, USA, and the World Health Organization.51 As an
example, the IMDRF has been instrumental in creating the risk categorization and
overall regulatory framework for SaMDs.52
Low- and middle-income countries (LMICs) face similar challenges in regulatory
design to the USA and EU, though oen with fewer regulatory resources.53 Some
LMICs address such resource limitations by recognizing approval from the FDA or CE
marking in Europe as a substitute for or supplement to their own regulatory review, and
such a pattern might be expected to continue with MML. AI governance frameworks
are also under development in multiple LMICs. For instance, India is developing a
governance framework, but both focus on AI generally rather than on medical AI
specically.54 International e orts are also spreading; in 2019, 42 countries, includ-
ing several LMICs, signed the OECD Principles on AI, which endorsed inclusivity,
diversity, transparency, and security, among other aims,55 though again not focused on
medical applications specically.
LMICs also face some unique issues.While recognizing that each regulatory setting
is distinct, we highlight two clusters of issues that play out slightly di erently in this
setting.
Data privacy, exportation, exploitation, and equitable access
Countries di er substantially when it comes to data privacy regulation. A 2018 survey
found that ‘101 countries have enacted general federal personal data protection laws, 12
countries have pending legislation, and 82 countries have neither enacted nor pending
legislation’.56 Of course, the picture becomes more complicated when it comes to
health, because somecountriesmay sectorally protect health caredatawithout a general
data protection regime (such as theUSHIPAAPrivacy Rule),57 while othersmay both
o er general data protection and also special additional rules for health privacy (such
as the EU’s GDPR).58 Furthermore, inferences about health can increasingly be made
from non-healthcare data, and used for many di erent purposes, such that many forms
of personal data may arguably become ‘health data’.59
51 Eg IMDRF, “Software as a Medical Device”: Possible Framework for Risk Categorization and Corresponding
Considerations, http://www.imdrf.org/docs/imdrf/nal/technical/imdrf-tech-140918-samd-framework-
risk-categorization-141013.pdf (accessed Jun. 15, 2019).
52 Susan Lamph, Regulation of medical devices outside the European Union, 105 J R Soc Med 12 (2012). See also
Madhumita Murgia, Siddarth Shrikanth, How governments are beginning to regulate AI, FT, May 30, 2019,
https://www..com/content/025315e8-7e4d-11e9-81d2-f785092ab560 (accessed Jun. 13, 2019).
53 For an overview of national AI strategies, see Tim Dutton, Articial Intelligence Strategies, https://medium.
com/politics-ai/an-overview-of-national-ai-strategies-2a70ec6edfd (accessed Jun. 14, 2019).
54 OECD, The OECD Principles on AI, https://www.oecd.org/going-digital/ai/principles/ (accessed June 14,
2019). OECD, Recommendation of the Council on Articial Intelligence, https://legalinstruments.oecd.
org/en/instruments/OECD-LEGAL-0449 (accessed Jun. 14, 2019).
55 Ronald N.Weikers, Megan Costello, Personal data protection laws around the world, 2 Data Sec. & Privacy Law
15 (2018).
56 Health Insurance Portability and Accountability Act of 1996, Pub. L. No. 104–191, 110 Stat. 1936. Standards
for Privacy of Individually Identiable Health Information, 45 C.F.R. pts. 160, 164 (2017).
57 Regulation (EU) 2016/679 of the European Parliament and of theCouncil of 27April 2016 on the protection
of natural persons with regard to the processing of personal data and on the free movement of such data, and
repealing Directive 95/46/EC (General Data Protection Regulation) [2016] OJ L119/1.
58 W. Nicholson Price II, I. Glenn Cohen, Privacy in the age of medical big data, 25 Nat Med. 37 (2019).
59 W. Nicholson Price II, Margot E. Kaminski, Timo Minssen, Kayte Spector-Bagdady, Shadow health records
meet new data privacy laws, 363 Science 448 (2019).
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Because privacy protections di er,60 companies seeking to develop MAI/MML
may face incentives to use data from LMICs with less stringent data protection, and
national governments may have strong incentives to sell or license patient data to big
players in the AI space—a phenomenon some refer to as ‘data colonization’. Some
countries, such as China, place stringent limitations on export of population data, but
many do not. When such deals result in benets to the patients whose data are used—
MMLusable in the country where the data originate, or proceed used to nance public
health or healthcare improvements—the deals can be appropriate. But as we have
seen with other forms of transnational medical practices, such as drug development or
medicalmigration, value createdoendoesnot owback to its LMICsources.Asnoted
in the OECD principles on AI, all players in the development of medical AI should
respect principles of equity, especially when using data from LMICs.
Data exportation could also result in data insecurity. Release of data from LMICs
should include verication both of strong cybersecurity practices on the recipient’s
part and of governance by well-established principles of sharing (such as the ‘Fair
Information Practice Principles’).61 These could include limitations on the amount
of data sharing, use only for pre-specied purposes, provisions for data destruction
aer use, and transparency about the contours of such data-sharing. Finally, because
breaches of health and other data have, unfortunately, become a fact of life, before
any sharing takes places LMICs should institute robust antidiscrimination and other
protections for their patients should their data be released.
Training set bias, contextual bias, and trade secrecy
An additional problem, in some tension with the rst, is bias. As multiple real-world
examples have shown,MAI can reach disturbingly inaccurate results depending on the
subject’s age or disabilities, ethnic origins,62 skin color63, or gender.64 False diagnoses
or improper treatment recommendations present a real threat to patient health. Such
biases can result fromnon-representative data, data-reecting biases in underlying care,
biases in the teams and development of MML, or many other interrelated sources. To
take an example of the rst, cardiomyopathy genetic tests have been found to be better
at identifying pathogenic variants in white patients than patients of other ethnicities
because of non-representative training data.65 MML trained on such data might pro-
vide poor results for non-white patients unless retrained on more representative data.
60 Iapp, Fair Information Practice Principles, https://iapp.org/resources/article/fair-information-practices/
(accessed Jun. 14, 2019).
61 Daniel Cossins, Discriminating algorithms: 5 times AI showed prejudice, NewScientist, Apr. 12, 2019,
https://www.newscientist.com/article/2166207-discriminating-algorithms-5-times-ai-showed-prejudice
(accessed Jun. 14, 2019).
62 Alex Fefegha, Racial Bias and Gender Bias Examples in AI systems, https://medium.com/thoughts-and-
reections/racial-bias-and-gender-bias-examples-in-ai-systems-7211e4c166a1 (accessed Jun. 14, 2019).
63 Eva Short, It turns out Amazon’s AI hiring tool discriminated against women, https://www.siliconrepublic.com/
careers/amazon-ai-hiring-tool-women-discrimination (accessed Jun. 14, 2019).
64 Latrice G. Landry, Heidi L. Rehm, Association of Racial/Ethnic Categories With the Ability of Genetic Tests to
Detect a Cause of Cardiomyopathy, 3 JAMA Cardiol 341 (2018). Arjun K. Manrai, Birgit H. Funke, Heidi L.
Rehm, Morten S. Olesen, Bradley A. Maron, Peter Szolovits, David M. Margulies, Joseph Loscalzo, Isaac S.
Kohane,Genetic Misdiagnoses and the Potential for Health Disparities, 375 N Engl J Med 655 (2016).
65 Id.
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When it comes to the use of MML developed in high-income settings for LMICs,
there is an additional risk of ‘contextual’ bias: algorithms trained to function in elite
hospitals with experts applying the technologymay not necessarily recommend appro-
priate, safe, and cost-e ective treatments in low-resource settings. With contextual
bias, even an algorithm trained on representatives’ populations (itself a feat) might
make improper recommendations. For example, in a leading cancer center it might be
best to recommend to a patient a powerful chemotherapeutic cocktail that requires
careful monitoring by an experienced oncology team to manage potentially deadly
side e ects, but that recommendation could be more likely to kill than to save the
patient in an LMIC (or rural, or non-specialist) hospital.66 In many cases, contextual
bias will be far more subtle. Contextual bias will be harder to detect in opaque MML
since the care-provider may not know the contextual variations making the algorithm’s
recommendation inappropriate for her setting. Such ignorance may be compounded
by secrecy among makers of MML.67 Soware companies in healthcare may oen
have good reasons to conceal their in-house testing procedures and other data for
competitive advantages or to refer to privacy protection.
Solutions are not easy here, especially if one expects that much MML will at least
initially be developed for high-income countries. More transparency about training
context and algorithmic limits will help, though competition concerns may hinder that
e ort. However, while knowing that a valuableMMLmay not work well in one’s coun-
try is better than not knowing, that knowledge does not help one’s countries patients
reap the MML’s benets. Longer-term solutions must incentivize MML makers to
design for LMIC needs. This may involve retraining on local population data but also
with local context inmind, or helping to build AI-development expertise for healthcare
in LMICs to begin with. But, it is unclear whether the LMIC markets are lucrative
enough to naturally push developers towards these options, or whether more direct
carrots (or sticks) are needed, not just from the LMICs themselves but also from high-
income countries.
CONCLUDINGREMARKS
Despite recent regulatory developments in the USA and Europe, there are currently
no harmonized standards or laws that specically regulate the use of MML-enabled
medical devices. In general, MML devices are currently reviewed to ensure compli-
ance with the regulatory requirements for all medical devices. The current regulatory
frameworks lag behind the use of MML, leading to regulatory uncertainty with risks
for manufacturers. MML manufacturers must spend substantial e ort and resources
to understand how regulations apply in the particular context of MML devices. This
includes working closely with the responsible regulatory authorities to achieve consis-
tency in interpretation. Positive developments in this specic area include FDA’s recent
discussion paper on continuously learningMML devices and IMDRF development of
foundational guidance intended to establish common SaMD denitions and develop
harmonized approaches for appropriate SaMD regulatory controls.
66 See eg Noel Sharkey, The impact of gender and race bias in AI. Humanitarian Law & Policy, https://blogs.icrc.
org/law-and-policy/2018/08/28/impact-gender-race-bias-ai/ (accessed Apr. 30, 2019).
67 OECD, Recommendation of the Council on Articial Intelligence, https://legalinstruments.oecd.org/en/
instruments/OECD-LEGAL-0449 (accessed Jun. 14, 2019).
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Medical device authoritiesmustmanage and administer an increasingly complicated
regulatory system. Accordingly, they are in need of experts with technical competency
to review the safety and e ectiveness of a new generation of MML-enabled devices
while taking into account complex considerations such as training set bias, contextual
bias, and how these technologieswill evolve across complex value chains and life cycles.
These considerations are important to be taken into account by the IMDRF as they
continue thework of theGHTF to acceleratemedical device regulatory harmonization
and convergence inorder to facilitate the global deployment ofMML innovationswhile
ensuring their safety and e ectiveness.
From a global policy perspective, a sustainable regulatory system of AI applications
in the health and life sciences should ensure that such new uses benet the global
populationbypromoting inclusive growth, sustainabledevelopment, andwell-being, as
noted in the recently adoptedOECDPrinciples onAI.68 In accordancewith these prin-
ciples, it will be important to embed respect for the rule of law, human rights, diversity,
and fairness, as well as other societal and democratic values in the design of AI systems
and devices.69 To implement and protect these values, AI systems should also include
appropriate safeguards, such as enabling human intervention where necessary.70 This
alsomeans thatMMLsystems should incorporate a reasonable amount of transparency
and responsible disclosure mechanism that allow medical practitioners, patients, and
their relatives to understand AI-based outcomes.71
Finally, to promote responsible stewardship of trustworthy and secure72 MML, as
well as a fair transition from traditional healthcare, it will be vital that governments
work together across border and sectors. Such international collaboration should also
extend to the education of medical practitioners, healthcare providers, patients, and
other stakeholders to increase their understanding of AI/ML73 and the associated
advantages, risks, and limitations of MML.
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